Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Am J Hum Genet ; 108(7): 1301-1317, 2021 07 01.
Article in English | MEDLINE | ID: mdl-34038740

ABSTRACT

Human C2orf69 is an evolutionarily conserved gene whose function is unknown. Here, we report eight unrelated families from which 20 children presented with a fatal syndrome consisting of severe autoinflammation and progredient leukoencephalopathy with recurrent seizures; 12 of these subjects, whose DNA was available, segregated homozygous loss-of-function C2orf69 variants. C2ORF69 bears homology to esterase enzymes, and orthologs can be found in most eukaryotic genomes, including that of unicellular phytoplankton. We found that endogenous C2ORF69 (1) is loosely bound to mitochondria, (2) affects mitochondrial membrane potential and oxidative respiration in cultured neurons, and (3) controls the levels of the glycogen branching enzyme 1 (GBE1) consistent with a glycogen-storage-associated mitochondriopathy. We show that CRISPR-Cas9-mediated inactivation of zebrafish C2orf69 results in lethality by 8 months of age due to spontaneous epileptic seizures, which is preceded by persistent brain inflammation. Collectively, our results delineate an autoinflammatory Mendelian disorder of C2orf69 deficiency that disrupts the development/homeostasis of the immune and central nervous systems.


Subject(s)
Encephalitis/genetics , Mitochondrial Diseases/genetics , Animals , Biological Evolution , CRISPR-Cas Systems , Cell Line , Encephalitis/mortality , Female , Genes, Recessive , Glycogen/metabolism , Humans , Inflammation/genetics , Male , Membrane Proteins/genetics , Mitochondrial Diseases/mortality , Pedigree , Seizures/genetics , Seizures/mortality , Zebrafish/genetics
3.
Clin Invest Med ; 39(6): 27511, 2016 Dec 01.
Article in English | MEDLINE | ID: mdl-27917801

ABSTRACT

PURPOSE: The purpose of this study was to evaluate the efficacy of Ginkgo biloba extract (EGb 761) on oxidative events of brain in cisplatin-administrated rats. METHODS: Rats were divided into four experimental groups: 1) control (n=6); 2) cisplatin (8 mg/kg, intraperitoneally one dose, n=6); 3) EGb 761 (100 mg/kg intraperitoneally for 15 days, n=6); and 4) cisplatin + EGb 761 (n=6). After drug administration, rats were sacrificed and brain tissues were removed. Nitric oxide (NO), malondialdehyde (MDA) and glutathione (GSH) levels were evaluated in brain tissues. RESULTS: Single dose cisplatin administration significantly increased NO and GSH levels, but decreased MDA levels in brain tissue samples. EGb 761 treatment reversed the effects of cisplatin on NO and GSH levels, but did not affect the decreased MDA levels. CONCLUSION: Results of the study indicate that oxidative stress can be an important pathogenetic mechanism of cisplatin-induced neurotoxicity. EGb 761, an standardized extract of G. biloba leaves that has antioxidant properties, may improve the oxidative stress-related neurological side effects of cisplatin.


Subject(s)
Brain/metabolism , Cisplatin/pharmacology , Ginkgo biloba/chemistry , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Animals , Brain Chemistry/drug effects , Female , Glutathione/metabolism , Malondialdehyde/metabolism , Nitric Oxide/metabolism , Plant Extracts/chemistry , Rats , Rats, Wistar
4.
Toxicol Ind Health ; 30(10): 888-95, 2014 Nov.
Article in English | MEDLINE | ID: mdl-23114375

ABSTRACT

The exposure of gastric mucosa to damaging factors, such as ethanol and some therapeutic drugs, produces pathological changes: inflammatory process, hemorrhagic erosions and even acute ulcers. Ankaferd blood stopper (ABS) comprises a standardized mixture of five different plant extracts. The purpose of our present investigations is to explain the participation of reactive oxygen species in acute gastric mucosal damage by acetylsalicylic acid (ASA) and the effects of new hemostatic agent ABS. Experiments were carried out on 23 male Wistar rats. To assess gastric mucosal damage, biochemical and histopathological data were used. The colorimetric assays were used to determine the malondialdehyde (MDA) and superoxide dismutase (SOD) activity. The level of myeloperoxidase (MPO) activity, the level of nitric oxide (NO) and the proinflammatory cytokine tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay technique. We demonstrated that the biological effects of ROS were estimated by measuring the tissue and plasma levels of MDA, the products of lipid peroxidation, as well as the activity of SOD and the scavenger of ROS produced by ASA in the experiment group. Moreover, it was found that MPO activity as well as NO and TNF-α levels also demonstrated significant improvement by ABS treatment. The pathogenesis of experimental ASA-induced mucosal damage in rat stomach includes the generation of ROS that seems to play an important role, due to the generation of lipid peroxides, accompanied by the impairment of antioxidative enzyme activity of cells. ABS appeared to attenuate the oxidative and inflammatory changes caused by ASA-induced gastric mucosal damage in rats.


Subject(s)
Aspirin/toxicity , Gastric Mucosa/drug effects , Gastric Mucosa/pathology , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Protective Agents/pharmacology , Animals , Disease Models, Animal , Gastric Mucosa/metabolism , Male , Rats , Rats, Wistar
5.
Turk J Med Sci ; 45(4): 959-63, 2015.
Article in English | MEDLINE | ID: mdl-26422874

ABSTRACT

BACKGROUND/AIM: We aimed to compare the effectiveness of esmolol 1 mg/kg and lidocaine 1 mg/kg for injection pain and for the prevention of rocuronium-induced withdrawal response. MATERIALS AND METHODS: We enrolled a total of 81 patients in the study. Patients were randomly assigned to receive either 10 mL of 0.9% NaCl (Group P), esmolol 1 mg/kg (Group E), or lidocaine 1.0 mg/kg (Group L). A subparalyzing dose of rocuronium 0.05 mg/ kg was administered to all patients and its effects were recorded. Anesthesia was induced with intravenous propofol and intravenous rocuronium 0.5 mg/kg in all groups. The withdrawal movements of the patient groups were subsequently graded. RESULTS: There was a statistically significant difference in overall incidence of pain in group E and L compared to the placebo group after administrating the subparalyzed dose (no pain response: Group E = 81.5%, Group L = 77.8%, Group P = 14.8%) (P < 0.001). After intravenous administration of an intubating dose of rocuronium, the esmolol group had a significantly lower incidence of withdrawal movement than the other groups (no response: Group E = 81.5%, Group L = 63%, Group P = 22.2%) (P < 0.001). CONCLUSION: We found that esmolol significantly attenuates rocuronium-induced withdrawal movement and also reduces pain when used at subparalyzing doses.


Subject(s)
Androstanols , Anesthesia, General/methods , Lidocaine/administration & dosage , Pain , Propanolamines/administration & dosage , Adrenergic beta-1 Receptor Antagonists/administration & dosage , Adult , Androstanols/administration & dosage , Androstanols/adverse effects , Anesthetics, Intravenous/administration & dosage , Double-Blind Method , Drug Monitoring , Female , Humans , Injections, Intravenous , Male , Middle Aged , Neuromuscular Nondepolarizing Agents/administration & dosage , Neuromuscular Nondepolarizing Agents/adverse effects , Pain/chemically induced , Pain/prevention & control , Pain Measurement/methods , Propofol/administration & dosage , Rocuronium , Substance Withdrawal Syndrome/prevention & control , Surgical Procedures, Operative/methods , Treatment Outcome
6.
J Ocul Pharmacol Ther ; 30(9): 700-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25100535

ABSTRACT

As an effective compound found mainly in the honeybee product propolis, caffeic acid phenethyl ester (CAPE) has been commonly utilized as a medicine and remedial agent, in a number of countries. Specifically, it might inhibit nuclear factor kappa B at micromolar concentrations and demonstrate antioxidant, antineoplastic, antiproliferative, cytostatic, antiviral, antibacterial, antifungal, and anti-inflammatory features. This review article summarizes the recent progress regarding the favorable effects of CAPE on a number of eye disease models, including cataract and posterior capsule opacification, corneal diseases, retina and optic nerve-related diseases, ischemia/reperfusion injury of retina, inflammation and infection-related diseases. CAPE has been found to exhibit promising efficacy, with minimal adverse effects, in animal and cell culture studies of several eye diseases.


Subject(s)
Caffeic Acids/pharmacology , Eye Diseases/prevention & control , NF-kappa B/antagonists & inhibitors , Phenylethyl Alcohol/analogs & derivatives , Animals , Bees , Caffeic Acids/adverse effects , Disease Models, Animal , Eye Diseases/physiopathology , Humans , Phenylethyl Alcohol/adverse effects , Phenylethyl Alcohol/pharmacology , Propolis/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL